The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Facility designed to advance the next generation of imaging systems
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
Findings likely to generate hypotheses about potential new uses of drugs
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
